The immunosuppressant FK506 uncovers a positive regulatory cross-talk between the Hog1p and Gcn2p pathways.
The immunosuppressant Tacrolimus (FK506) has increased the survival rates of organ transplantation. FK506 exerts its immunosuppressive effect by inhibition of the protein phosphatase calcineurin in activated T-cells. Unfortunately, FK506 therapy is associated with undesired non-therapeutic effects involving targets other than calcineurin. To identify these targets we have addressed FK506 cellular toxicity in budding yeast. We show that FK506 increased cell sensitivity upon osmotic challenge independently of calcineurin and the FK506-binding proteins Fpr1p, -2p, -3p, and -4p. FK506 also induced strong amino acid starvation and activation of the general control (GCN) pathway. Tryptophan prototrophy or excess tryptophan overcame FK506 toxicity, showing that tryptophan deprivation mediated this effect. Mutation of the GCN3 and -4 genes partially alleviated FK506 toxicity, suggesting that activation of the GCN pathway by FK506 was also involved in osmotic tolerance. FK506 enhanced osmotic stress-dependent Hog1p kinase phosphorylation that was not accompanied by induction of a Hog1p-dependent reporter. Interestingly, deletion of the GCN2 gene suppressed FK506-dependent Hog1p hyperphosphorylation and restored Hog1p-dependent reporter activity. Conversely, deletion of the HOG1 gene impaired FK506-dependent activation of Gcn2p kinase and translation of a GCN4-LacZ reporter, highlighting functional cross-talk between the Gcn2p and Hog1p protein kinases. Taken together, these data demonstrate that both FK506-induced amino acid starvation and activation of the GCN pathway contribute to cell sensitivity to osmotic stress and reveal a positive regulatory loop between the Hog1p and Gcn2p pathways. Given the conserved nature of Gcn2p and Hog1p pathways, this mechanism of FK506 toxicity could be relevant to the non-therapeutic effects of FK506 therapy.
Rodriguez-Hernandez
Carlos J
CJ
Research Unit, Hospital Universitario de Canarias, Ofra s/n-La Cuesta, 38320-La Laguna, Spain.
Sanchez-Perez
Isabel
I
Gil-Mascarell
Rosario
R
Rodríguez-Afonso
Abigail
A
Torres
Armando
A
Perona
Rosario
R
Murguia
José R
JR
D019703:Calcineurin / Q000378:metabolism; D017353:Gene Deletion; D017930:Genes, Reporter; D015151:Immunoblotting; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007202:Indicators and Reagents / Q000494:pharmacology; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009154:Mutation; D009995:Osmosis; D010766:Phosphorylation; D010957:Plasmids / Q000378:metabolism; D011485:Protein Binding; D014176:Protein Biosynthesis; D011494:Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases; D012441:Saccharomyces cerevisiae / Q000378:metabolism; D029701:Saccharomyces cerevisiae Proteins / Q000378:metabolism*; D013012:Sorbitol / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology*; D013997:Time Factors; D014364:Tryptophan / Q000737:chemistry / Q000378:metabolism; D001616:beta-Galactosidase / Q000378:metabolism
D007166:Immunosuppressive Agents; D007202:Indicators and Reagents; D029701:Saccharomyces cerevisiae Proteins; D013012:Sorbitol; D014364:Tryptophan; D011494:Protein Kinases; C512912:GCN2 protein, S cerevisiae; D017346:Protein Serine-Threonine Kinases; C088589:HOG1 protein, S cerevisiae; D020928:Mitogen-Activated Protein Kinases; D019703:Calcineurin; D001616:beta-Galactosidase; D016559:Tacrolimus